In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. Of 9,225 ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in mice to a hundred times its stand-alone effectiveness, thus offering ...

The mRNA COVID-19 vaccines might make some cancer treatments more effective. Lung cancer patients who received the vaccine within a few months of immunotherapy, which revs up the immune system, lived ...

COVID-19 mRNA vaccines create enough of an immunity boost to extend survival in certain types of lung and skin cancers, an analysis of more than 1,000 patient files showed. The scientific journal ...

The researchers found that mRNA-based COVID-19 vaccines could potentially help patients whose tumors don’t respond well to traditional immunotherapy. When you purchase through links on our site, we ...

WASHINGTON (AP) — The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients – revving up their immune systems to help fight tumors. People with advanced lung or skin ...

A new study has found that receiving messenger RNA-based COVID-19 vaccines such as those from Pfizer (NYSE:PFE)/BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) could boost the survival rates of ...

The mRNA covid-19 vaccines seem to have an unexpected benefit: extending the lives of people being treated for cancers by boosting the effectiveness of immunotherapy. An analysis of the records of ...

Vaccines that resemble viruses generally produce a stronger immune response, while mRNA versions are much quicker and cheaper to make. Now we are getting the best of both worlds, in the form of mRNA ...

Deborah Fuller receives funding from the National Institutes of Health. She is co-founder and a scientific advisor for two biotech companies developing nucleic acid vaccine technologies that are not ...